Race Oncology Ltd has released a press release.
Bonus Options Prospectus
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Updated Strategy and Investor Presentation
- Dr Daniel Tillett appointed CEO of Race Oncology
- RC220 Meets Quality Specifications
- Impressive Bisantrene Phase 2 AML Clinical Results
- Trading Halt
Later from Racura Oncology
- December 2023 Preclinical & Clinical Program Update
- Race Receives $4.0m R&D Tax Refund for Financial Year 2023
- S&P DJI Announces March 2024 Quarterly Rebalance
- Bisantrene shows potent anticancer activity in AML models
- RC220 cGMP Manufacturing Complete
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology